ConductScience.org, home

Paper8575136

Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study.

Spadaro A and 5 others. Clin Exp Rheumatol, 1995. Cited by 103 papers, by iCite.

Cite this record

ConductScience Library. Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study. Papers, record 8575136. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8575136

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study.
PubMed
Journal
Clin Exp Rheumatol
PubMed
Year
1995
PubMed
Publication types
Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial
PubMed
Citations, by iCite
103
iCite
Relative citation ratio, by iCite
3.95
iCite
Revised in PubMed
2017-01-12
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Spadaro AA
2Riccieri VV
3Sili-Scavalli AA
4Sensi FF
5Taccari EE
6Zoppini AA

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antirheumatic AgentsMajor topic
Arthritis, PsoriaticMajor topic
CyclosporineMajor topic
MethotrexateMajor topic
Adolescent
Adult
Aged
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Follow-Up Studies
Humans
Male
Middle Aged
Prospective Studies
Treatment Outcome

Source PubMed

Download CSV of topics

Cited by22

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 103 citations.

PMIDTitleJournalYearIn PapersSource
34819174Brazilian Society of Rheumatology 2020 guidelines for psoriatic arthritis.Adv Rheumatol2021https://conductscience.org/library/papers/34819174PubMed
33934175Management of particular clinical situations in psoriatic arthritis: an expert's recommendation document based on systematic literature review and extended Delphi process.Rheumatol Int2021https://conductscience.org/library/papers/33934175PubMed
30656673Methotrexate for psoriatic arthritis.Cochrane Database Syst Rev2019https://conductscience.org/library/papers/30656673PubMed
28293446
Real-life experience of using conventional disease-modifying anti-rheumatic drugs (DMARDs) in psoriatic arthritis (PsA). Retrospective analysis of the efficacy of methotrexate, sulfasalazine, and leflunomide in PsA in comparison to spondyloarthritides other than PsA and literature review of the use of conventional DMARDs in PsA.
Eur J Rheumatol2017https://conductscience.org/library/papers/28293446PubMed
27515671The Use of Cyclosporine A in Rheumatology: a 2016 Comprehensive Review.Clin Rev Allergy Immunol2017https://conductscience.org/library/papers/27515671PubMed
22344575A randomized placebo-controlled trial of methotrexate in psoriatic arthritis.Rheumatology (Oxford)2012https://conductscience.org/library/papers/22344575PubMed
21979255[Psoriatric arthritis - a permanent challenge for rheumatologists and patients: part 2: imaging diagnostics, classification and therapy].Z Rheumatol2011https://conductscience.org/library/papers/21979255PubMed
21272347
Change in CD3 positive T-cell expression in psoriatic arthritis synovium correlates with change in DAS28 and magnetic resonance imaging synovitis scores following initiation of biologic therapy--a single centre, open-label study.
Arthritis Res Ther2011https://conductscience.org/library/papers/21272347PubMed
19691930Update on the treatment of peripheral arthritis in psoriatic arthritis.Curr Rheumatol Rep2009https://conductscience.org/library/papers/19691930PubMed
18177596Psoriatic arthritis: current topics.Curr Rheumatol Rep2007https://conductscience.org/library/papers/18177596PubMed
17102998[Therapy for secondary arthropathies: from psoriasis and Reiter's disease to hemochromatosis].Internist (Berl)2006https://conductscience.org/library/papers/17102998PubMed
17038465Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.Ann Rheum Dis2006https://conductscience.org/library/papers/17038465PubMed
16239380
Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.
Ann Rheum Dis2005https://conductscience.org/library/papers/16239380PubMed
15916449Traditional and newer therapeutic options for psoriatic arthritis: an evidence-based review.Drugs2005https://conductscience.org/library/papers/15916449PubMed
15708943Psoriatic arthritis therapy: NSAIDs and traditional DMARDs.Ann Rheum Dis2005https://conductscience.org/library/papers/15708943PubMed
15528283A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis.Ann Rheum Dis2005https://conductscience.org/library/papers/15528283PubMed
15479866
Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.
Ann Rheum Dis2004https://conductscience.org/library/papers/15479866PubMed
12421102Diagnosis and management of psoriatic arthritis.Drugs2002https://conductscience.org/library/papers/12421102PubMed
11890649Treatment of active spondyloarthropathy with infliximab, the chimeric monoclonal antibody to tumour necrosis factor alpha.Ann Rheum Dis2001https://conductscience.org/library/papers/11890649PubMed
11830424Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up.Ann Rheum Dis2002https://conductscience.org/library/papers/11830424PubMed

See all 22 cited byDownload CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CRP1401PubTator's text mininghttps://conductscience.org/library/genes/1401NCBI Gene
SLC17A526503PubTator's text mininghttps://conductscience.org/library/genes/26503NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/8575136

GET https://conductscience.org/api/papers/v1/8575136/cited_by?page=2